Literature DB >> 30382376

Neonatal intestinal organoids as an ex vivo approach to study early intestinal epithelial disorders.

Bo Li1, Carol Lee1, Marissa Cadete1, Hiromu Miyake1, Dorothy Lee1, Agostino Pierro2.   

Abstract

BACKGROUND: Adult intestinal organoids have been used to study ex vivo intestinal injury in adulthood. However, the neonatal intestinal epithelium has many unique features that are different from adult mature intestine. Establishing a neonatal ex vivo organoid model is essential to study the epithelial physiology in early postnatal development and to investigate derangements associated with disease processes during the neonatal period like necrotizing enterocolitis (NEC).
METHODS: Fresh and frozen terminal ileum was harvested from mice pups on postnatal day 9. Crypts were isolated and organoids were cultured. Organoids were exposed to hypoxia and lipopolysaccharide (LPS) for 48 h to induce epithelial injury. Inflammatory cytokines and tight junction proteins were evaluated.
RESULTS: Robust intestinal organoids can be formed from both fresh and frozen intestinal tissue of neonatal mice pups. Hypoxia and LPS administration induced intestinal inflammation and disrupted tight junctions in these neonatal intestinal organoids.
CONCLUSIONS: We have established a novel method to grow organoids from neonatal intestine. We demonstrated that these organoids respond to the injury occurring during neonatal intestinal diseases such as NEC by increasing the organoid inflammation and by disrupting the organoid barrier function. Organoids provide an ex vivo platform to study intestinal physiology and pathology during the neonatal period.

Entities:  

Keywords:  Intestinal organoids; Necrotizing enterocolitis; Neonatal intestinal injury; Stress factors

Mesh:

Substances:

Year:  2018        PMID: 30382376     DOI: 10.1007/s00383-018-4369-3

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  6 in total

Review 1.  Intestinal organoids in infants and children.

Authors:  Sinobol Chusilp; Bo Li; Dorothy Lee; Carol Lee; Paisarn Vejchapipat; Agostino Pierro
Journal:  Pediatr Surg Int       Date:  2019-09-25       Impact factor: 1.827

Review 2.  The benefits, limitations and opportunities of preclinical models for neonatal drug development.

Authors:  Sarah Campion; Amy Inselman; Belinda Hayes; Costanza Casiraghi; David Joseph; Fabrizio Facchinetti; Fabrizio Salomone; Georg Schmitt; Julia Hui; Karen Davis-Bruno; Karen Van Malderen; LaRonda Morford; Luc De Schaepdrijver; Lutz Wiesner; Stephanie Kourula; Suna Seo; Susan Laffan; Vijay Urmaliya; Connie Chen
Journal:  Dis Model Mech       Date:  2022-04-25       Impact factor: 5.732

3.  DRG1 Maintains Intestinal Epithelial Cell Junctions and Barrier Function by Regulating RAC1 Activity in Necrotizing Enterocolitis.

Authors:  Li Lu; Weijue Xu; Jiangbin Liu; Liping Chen; Shaohua Hu; Qingfeng Sheng; Minghua Zhang; Zhibao Lv
Journal:  Dig Dis Sci       Date:  2021-01-20       Impact factor: 3.199

Review 4.  Necrotizing Enterocolitis: Overview on In Vitro Models.

Authors:  Luigia De Fazio; Isadora Beghetti; Salvatore Nicola Bertuccio; Concetta Marsico; Silvia Martini; Riccardo Masetti; Andrea Pession; Luigi Corvaglia; Arianna Aceti
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

Review 5.  Precision-based modeling approaches for necrotizing enterocolitis.

Authors:  Mark L Kovler; Chhinder P Sodhi; David J Hackam
Journal:  Dis Model Mech       Date:  2020-06-24       Impact factor: 5.758

6.  Impaired Wnt/β-catenin pathway leads to dysfunction of intestinal regeneration during necrotizing enterocolitis.

Authors:  Bo Li; Carol Lee; Marissa Cadete; Haitao Zhu; Yuhki Koike; Alison Hock; Richard Y Wu; Steven R Botts; Adam Minich; Mashriq Alganabi; Lijun Chi; Elke Zani-Ruttenstock; Hiromu Miyake; Yong Chen; Annika Mutanen; Bo Ngan; Kathene C Johnson-Henry; Paolo De Coppi; Simon Eaton; Pekka Määttänen; Paul Delgado-Olguin; Philip M Sherman; Augusto Zani; Agostino Pierro
Journal:  Cell Death Dis       Date:  2019-10-03       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.